Cargando…
Mutations within the Activation Loop Domain of FLT3 in Two Pediatric Patients with Refractory Infant Acute Myeloid Leukemia
Approximately 24% of all pediatric acute myeloid leukemia (AML) cases have mutations in the FMS-like tyrosine kinase 3 (FLT3) receptor gene. FLT3-TKD point mutations are rare in pediatrics and often occur in younger patients and in combination with 11q23 abnormalities. There is a paucity of data rel...
Autores principales: | Muhlbauer, Nicole, MacDonell-Yilmaz, Rebecca E., Borsuk, Robyn, Welch, Jennifer G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154245/ https://www.ncbi.nlm.nih.gov/pubmed/32308588 http://dx.doi.org/10.1159/000506194 |
Ejemplares similares
-
Gilteritinib in the treatment of relapsed and refractory acute
myeloid leukemia with a FLT3 mutation
por: Chew, Serena, et al.
Publicado: (2020) -
Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia
por: Marjoncu, Dennis, et al.
Publicado: (2020) -
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
por: Daver, Naval, et al.
Publicado: (2022) -
FLT4 as a marker for predicting prognostic risk of refractory acute myeloid leukemia
por: Lee, Ji Yoon, et al.
Publicado: (2023) -
Cost-effectiveness of gilteritinib for relapsed/refractory FLT3(mut+) acute myeloid leukemia
por: Pandya, Bhavik J, et al.
Publicado: (2021)